Related Experiment Video
Updated: Jan 27, 2026
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
cAMP-enriched extracellular vesicles improve outcomes in pulmonary hypertension
Aritra Bhadra1, Frederic Bonnie1, Jenny Hewes1,2
1Department of Pharmacology, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, Alabama, United States.
None:
Extracellular vesicles (EVs) containing cyclic adenosine monophosphate (cAMP-EVs) activate signaling based on protein kinase A in recipient endothelial cells, but limited information is available about the function of cAMP-EVs under physiologic or pathologic conditions. We evaluated the effects of treatment with cAMP-EVs in Sprague-Dawley rats with hypoxia-induced pulmonary hypertension. Rats were exposed to hypoxia (10% oxygen) or normoxia for 3 wk, and the hypoxic rats received no injection or tail vein injection with cAMP-EVs or control EVs during the final 3 days of hypoxia. The ratio of pulmonary artery acceleration time to pulmonary artery ejection time was higher, and the Fulton index was lower, in hypoxic rats treated with cAMP-EVs compared with those receiving no treatment. Confocal microscopy with PKH red-stained EVs showed higher fluorescence in lung tissue from hypoxic rats treated with cAMP-EVs versus no treatment. Hypoxic rats treated with cAMP-EVs had lower arterial wall thickness, higher protein kinase A activity, and higher endothelial nitric oxide synthase phosphorylation than untreated rats. Our coculture studies showed that stimulation of pulmonary endothelial cells with cAMP-EVs under hypoxic conditions inhibited PASMC proliferation, whereas no significant effect was observed under normoxia. These results provide evidence that second messenger molecules, such as cAMP packaged in EVs, help improve pathological conditions, including pulmonary hypertension.NEW & NOTEWORTHY Treatment with extracellular vesicles containing cyclic adenosine monophosphate (cAMP-EVs) improved outcomes of pulmonary hypertension in rats with hypoxia-induced pulmonary hypertension. Furthermore, the signaling events relative to these outcomes are likely endothelial-dependent and do not require the β-adrenergic receptor. These results suggest that cAMP-EVs help improve pulmonary hypertension and further our understanding of cAMP signaling in the pulmonary circulation.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...